138,802 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 138,802 shares of the company’s stock, valued at approximately $19,686,000. Neurocrine Biosciences accounts for approximately 9.9% of PKO BP BANKOWY Universal Pension Society JSC’s portfolio, making the stock its 5th largest position.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in Neurocrine Biosciences by 11.0% during the third quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after acquiring an additional 468,405 shares during the period. AQR Capital Management LLC grew its holdings in Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after purchasing an additional 1,263,633 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Neurocrine Biosciences by 1.4% in the third quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock valued at $166,258,000 after purchasing an additional 16,543 shares during the last quarter. UBS Group AG grew its holdings in Neurocrine Biosciences by 169.8% in the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after purchasing an additional 618,956 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in Neurocrine Biosciences by 12.0% in the fourth quarter. Pictet Asset Management Holding SA now owns 776,934 shares of the company’s stock valued at $110,305,000 after purchasing an additional 83,488 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 0.8%

Shares of NASDAQ:NBIX opened at $157.21 on Tuesday. Neurocrine Biosciences, Inc. has a 52-week low of $117.59 and a 52-week high of $162.39. The stock’s fifty day simple moving average is $134.60 and its 200-day simple moving average is $138.45. The company has a market capitalization of $15.81 billion, a P/E ratio of 24.22, a P/E/G ratio of 1.19 and a beta of 0.34.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 3,810 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total value of $590,588.10. Following the sale, the director directly owned 2,429 shares in the company, valued at $376,519.29. This represents a 61.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total value of $2,364,750.00. Following the completion of the sale, the director owned 34,480 shares in the company, valued at $5,435,772. This represents a 30.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

NBIX has been the topic of several research reports. Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Zacks Research raised Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Needham & Company LLC reissued a “buy” rating and issued a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Tuesday, April 21st. Finally, Morgan Stanley upped their target price on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $184.15.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.